POMC and focal segmental glomerulosclerosis: Stable doses of concurrent immunosuppression were permitted.<h4>Diagnoses</h4>Membranous nephropathy, IgA nephropathy, minimal change disease, and focal and segmental glomerulosclerosis.<h4>Intervention</h4>Intramuscular synthetic adrenocorticotropic hormone (Tetracosactide, Synacthen Depot) with doses of either 1 mg weekly or 1 mg twice weekly.<h4>Outcomes</h4>Five of 12 patients had at least a partial remission with Tetracosactide.